Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design
AbstractHerein we present, an exhaustive docking analysis considering the case of autotaxin (ATX). HA155, a small molecule inhibitor of ATX, is co-crystallized. In order to further extract conclusions on the nature of the bond formed between the ligands and the amino acid residues of the active site, density functional theory (DFT) calculations were undertaken. However, docking does not provide reproducible results when screening boronic acid derivatives and their binding orientations to protein drug targets. Based on natural bond orbital (NBO) calculations, the formed bond between Ser/Thr residues is characterized more accurately as a polar covalent bond instead of a simple nonpolar covalent one. The presented results are acceptable and could be used in screening as an active negative filter for boron compounds. The hydroxyl groups of amino acids are bonded with the inhibitor’s boron atom, converting its hybridization to sp3. View Full-Text
Share & Cite This Article
Katsamakas, S.; Papadopoulos, A.G.; Hadjipavlou-Litina, D. Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design. Molecules 2016, 21, 1185.
Katsamakas S, Papadopoulos AG, Hadjipavlou-Litina D. Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design. Molecules. 2016; 21(9):1185.Chicago/Turabian Style
Katsamakas, Sotirios; Papadopoulos, Anastasios G.; Hadjipavlou-Litina, Dimitra. 2016. "Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design." Molecules 21, no. 9: 1185.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.